Stopping Cancer Before It Starts

Antiva is developing novel topical therapies to treat pre-cancerous lesions caused by HPV. Our passionate, experienced team is dedicated to improving health outcomes and access to care worldwide. We aim to empower patients with safe, effective treatment options, address health care disparities in underserved communities, and save lives globally. Our non-surgical treatment approach offers a simple and convenient alternative to stop HPV and precancerous lesions before they become cancer.

Antiva in the

January 6, 2022

Antiva Biosciences Named Winner of Global Women’s HealthTech Award by World Bank Group and Consumer Technology Association Read more

November 2, 2021

Antiva Biosciences Closes $31 Million Series D Equity Financing Read more

April 21, 2021

Antiva Biosciences Appoints Clifford Samuel to Board of Directors Read more